Achieve Life Sciences, Inc.
ACHVHealthcare|Biotechnology|US
$6.72
+0.34 (+5.41%)
DCF Value
$0.12
Cash / Share
$2.00
Clinical Trials (37)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01188187 Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer | Prostate Cancer | P3 | Completed | 1,022 | RCT, Open-label | Custirsen, Docetaxel, Prednisone, Dexamethasone |
| NCT00251095 Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer | Breast Neoplasm | P3 | Terminated | 821 | RCT, Open-label | Taxol, TOCOSOL Paclitaxel |
| NCT01578655 Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer | Prostate Cancer | P3 | Completed | 630 | RCT, Open-label | cabazitaxel, prednisone, custirsen sodium |
| NCT06435221 Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers | Smoking Cessation, Vaping Cessation | P3 | Completed | 479 | Open-label | Cytisinicline |
| NCT01083615 A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | P3 | Terminated | 14 | RCT, Double-blind | custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone |
| NCT01630733 A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P3 | Completed | 664 | RCT, Open-label | Custirsen, Docetaxel |
| NCT07392125 Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | Vaping Cessation | P3 | Not Yet Recruiting | 800 | RCT, Double-blind | Cytisinicline, Placebo |
| NCT05206370 A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers | Smoking Cessation | P3 | Completed | 792 | RCT, Double-blind | Cytisinicline, Placebo |
| NCT04576949 A Study of Cytisinicline for Smoking Cessation in Adult Smokers | Smoking Cessation | P3 | Completed | 810 | RCT, Double-blind | Cytisinicline, Placebo |
| NCT03303911 A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers | Smoking Cessation | P1P2 | Terminated | 26 | RCT, Open-label | Cytisine |
| NCT05431387 A Study of Cytisinicline for Vaping Cessation in Adult Smokers | Vaping, E-Cig Use | P2 | Completed | 160 | RCT, Double-blind | cytisinicline, Placebo |
| NCT00034190 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma | Colorectal Adenocarcinoma | P2 | Completed | 28 | Open-label | S-8184 Paclitaxel Injectable Emulsion |
| NCT00327340 Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | Prostate Cancer | P2 | Completed | 70 | RCT, Open-label | custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel |
| NCT00034177 Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | Urologic Neoplasms | P2 | Completed | 27 | Open-label | S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel |
| NCT01681433 OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer | P2 | Terminated | 72 | RCT, Open-label | OGX-427, Abiraterone Acetate, Prednisone |
| NCT00096668 Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 47 | Open-label | TOCOSOL(R) Paclitaxel |
| NCT01829113 Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | P2 | Completed | 155 | RCT, Double-blind | OGX-427, Placebo |
| NCT00138658 A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P1P2 | Completed | 85 | Open-label | custirsen sodium |
| NCT00077688 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | Bladder Neoplasms, Ureteral Neoplasms | P2 | Completed | 44 | Open-label | TOCOSOL Paclitaxel |
| NCT01844817 Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Completed | 132 | RCT, Double-blind | OGX-427, Placebo |
| NCT00034151 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | Ovarian Cancer | P2 | Completed | 52 | Open-label | S-8184 Paclitaxel Injectable Emulsion |
| NCT00034164 Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 52 | Open-label | S-8184 Paclitaxel Injectable Emulsion |
| NCT02423590 Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | Squamous Cell Lung Cancer | P2 | Unknown | 140 | RCT, Open-label | Apatorsen (OGX-427), Gemcitabine, Carboplatin |
| NCT01454089 A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | Urologic Neoplasms, Metastatic Bladder Cancer | P2 | Completed | 183 | RCT, Double-blind | OGX-427 600 mg, OGX-427 1000 mg, Placebo, Gemcitabine, Cisplatin, Carboplatin |
| NCT01120470 OGX-427 in Castration Resistant Prostate Cancer Patients | Castration Resistant Prostate Cancer | P2 | Completed | 74 | RCT, Open-label | OGX-427, Prednisone |
| NCT01780545 Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | Bladder Cancer, Urothelial Carcinoma | P2 | Completed | 200 | RCT, Open-label | OGX-427, Docetaxel |
| NCT03709823 Trial of Cytisine in Adult Smokers | Smoking Cessation | P2 | Completed | 254 | RCT, Double-blind | Cytisine, Placebo Comparator |
| NCT01497470 A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen | Cancer | P1 | Completed | 36 | Open-label | Custirsen, paclitaxel and carboplatin |
| NCT01874561 Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization | Cardiac Conduction and Repolarization | P1 | Completed | 155 | RCT, Double-blind | Custirsen, Placebo, Moxifloxacin |
| NCT05566288 Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers | Smoking Cessation | P1 | Completed | 27 | RCT, Double-blind | Cytisinicline, Placebo, Moxifloxacin |
| NCT05981768 Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers | Smoking Cessation | P1 | Completed | 30 | RCT, Open-label | Cytisinicline |
| NCT00487786 Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer | Neoplasms | P1 | Completed | 64 | Open-label | OGX-427, Docetaxel |
| NCT03509948 A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation | Smoking Cessation | P1 | Completed | 13 | RCT, Open-label | cytisine |
| NCT03848208 A Single Dose-escalation Study of Cytisine in Adult Smokers | Smoking Cessation | P1 | Completed | 74 | RCT, Double-blind | cytisine, placebo |
| NCT05631938 Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose | Renal Impairment | P1 | Completed | 44 | Open-label | cytisinicline |
| NCT03268343 A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine | Smoking Cessation | P1 | Completed | 24 | RCT, Open-label | Cytisine |
| NCT00385177 Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors | Breast Neoplasms, Colorectal Neoplasms | P1 | Completed | 61 | Open-label | SN2310 Injectable Emulsion |